f Skin Rash after Camrelizumab and Sorafenib in a Patient with Advanced Hepatocellular Carcinoma

References

1. BlanchetB. BillemontB. BareteS. GarrigueH. CabanesL. CoriatR. FrancèsC. KnebelmannB. GoldwasserF. Toxicity of sorafenib: Clinical and molecular aspects.Expert Opin. Drug Saf.20109227528710.1517/14740330903510608 20078249
   [Google Scholar]
2. SangroB. ChanS.L. MeyerT. ReigM. El-KhoueiryA. GalleP.R. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.J. Hepatol.202072232034110.1016/j.jhep.2019.10.021 31954495
   [Google Scholar]
3. HaanenJ.B.A.G. CarbonnelF. RobertC. KerrK.M. PetersS. LarkinJ. JordanK. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann. Oncol.201728Suppl. 411914210.1093/annonc/mdx225 28881921
   [Google Scholar]
4. BrahmerJ.R. LacchettiC. SchneiderB.J. AtkinsM.B. BrassilK.J. CaterinoJ.M. ChauI. ErnstoffM.S. GardnerJ.M. GinexP. HallmeyerS. Holter ChakrabartyJ. LeighlN.B. MammenJ.S. McDermottD.F. NaingA. NastoupilL.J. PhillipsT. PorterL.D. PuzanovI. ReichnerC.A. SantomassoB.D. SeigelC. SpiraA. Suarez-AlmazorM.E. WangY. WeberJ.S. WolchokJ.D. ThompsonJ.A. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline.J. Clin. Oncol.201836171714176810.1200/JCO.2017.77.6385 29442540
   [Google Scholar]